secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0000950170-22-010075
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta CMO Kanya Rajangam resigns; David Shook named VP Clinical Development
----------------------------------------------------------------------------

- Dr. Kanya Rajangam resigns as CMO effective June 5, 2022, to oversee R&D at a private biotech.
- Dr. David Shook appointed VP Clinical Development, leading all clinical and regulatory activities.
- Shook is a practicing pediatric hematologist/oncologist and early NK cell therapy pioneer.
- Nkarta's NKX101 and NKX019 programs continue; expects to submit updated data for a medical meeting in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/0000950170-22-010075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/nktx-20220513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-010075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer